Latest News

Biosensia appoints James D. Merselis as Non-Executive Director.

Dublin, 23 October 2012 … Biosensia ltd., a Seroba Kernel backed point of care diagnostics Company, today announces the appointment of James D. Merselis as Non-Executive Director. Jim is currently a non-executive director at Trinity Biotech (NASDAQ: TRIB) and a consultant to healthcare diagnostics companies. He was formerly President and CEO of ITC Nexus Dx, Inc, a privately...


Covagen enters into a strategic research collaboration and license agreement with Mitsubishi Tanabe for the development of bispecific FynomAbs.

ZURICH-SCHLIEREN, Switzerland, Oct. 17, 2012 - Covagen announced today that it has entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) and its fully owned subsidiary Tanabe Research Laboratories U.S.A., Inc. of San Diego Calif. (TRL). Under the agreement, Covagen will use its proprietary Fynomer...


Novel 3D Stent Demonstrates Safety and Efficacy in Treatment of PAD

Las Vegas, USA, 11 October 2012. – New data presented today at the annual VIVA (Vascular InterVentional Advances) conference has shown that a stent with unique three-dimensional geometry, BioMimics 3D™, demonstrated an excellent safety profile and promising clinical performance at both six and twelve months in the treatment of patients with peripheral arterial disease (PAD)...


< back to home page